CRANBURY, N.J., Aug. 6, 2019 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE American: PTN) announced today that it
will be presenting at Canaccord Genuity's 39th Annual
Growth Conference on Wednesday, August 7,
2019, at 10:30 am ET.
The conference will be held at the InterContinental Hotel in
Boston, MA.
Carl Spana, Ph.D., President and
Chief Executive Officer of Palatin Technologies, will provide an
update on Palatin's corporate and development programs,
including:
- Hypoactive Sexual Desire Disorder / Vyleesi™
(bremelanotide injection)
-
- On June 21, 2019, the U.S. Food
and Drug Administration (FDA) granted marketing approval of AMAG
Pharmaceuticals, Inc's New Drug Application (NDA) for Vyleesi, a
melanocortin receptor agonist developed by Palatin, indicated for
the treatment of acquired, generalized hypoactive sexual desire
disorder (HSDD) in premenopausal women. The Vyleesi autoinjector is
the first treatment for this patient population that can be
self-administered as needed in anticipation of sexual
activity.
- The FDA's approval of the NDA triggered a $60 million milestone payment to Palatin
(received July 2019) under its North
American license agreement with AMAG.
- AMAG is expected to launch Vyleesi nationally in September 2019.
- Discussions with multiple parties on potential commercial
partnerships for territories outside North America, China and South
Korea are advancing.
- Melanocortin Anti-Inflammatory / Autoimmune Programs under
development for the treatment of inflammatory and autoimmune
diseases such as dry eye, uveitis, diabetic retinopathy and
inflammatory bowel diseases (ulcerative colitis)
-
- A Phase 2 proof-of-concept clinical study for PL-8177 with a
systemic formulation in NIU patients is anticipated to commence in
the first quarter of calendar year 2020.
- A Phase 2 proof-of-concept clinical study for PL-8177 with an
oral formulation in ulcerative colitis patients is anticipated to
commence in the first quarter of calendar year 2020.
- A Phase 2 clinical study for PL-9643 in dry eye disease is
currently anticipated to commence in the first quarter of calendar
year 2020. A recently completed Type B pre-IND (Investigational New
Drug) meeting with the FDA established the development pathway for
activities, including CMC, non-clinical studies and clinical
studies, required for an NDA (New Drug Application)
submission.
- Cash and cash equivalents at June 30,
2019, on a pro forma basis, which includes the $60 million milestone payment by exclusive North
American licensee, AMAG Pharmaceuticals, Inc., is approximately
$102 million dollars.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is a biopharmaceutical company developing
targeted, receptor-specific peptide therapeutics for the treatment
of diseases and conditions with significant unmet medical need and
commercial potential. Palatin's strategy is to develop products and
then form marketing collaborations with industry leaders in order
to maximize their commercial potential. For additional information
regarding Palatin, please visit Palatin's website at
www.Palatin.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-to-present-at-canaccord-genuitys-39th-annual-growth-conference-300896933.html
SOURCE Palatin Technologies, Inc.